254 related articles for article (PubMed ID: 32337054)
1. Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study.
Marin-Jimenez I; Bastida G; Forés A; Garcia-Planella E; Argüelles-Arias F; Sarasa P; Tagarro I; Fernández-Nistal A; Montoto C; Aguas M; Santos-Fernández J; Bosca-Watts MM; Ferreiro R; Merino O; Aldeguer X; Cortés X; Sicilia B; Mesonero F; Barreiro-de Acosta M
BMJ Open Gastroenterol; 2020; 7(1):e000351. PubMed ID: 32337054
[TBL] [Abstract][Full Text] [Related]
2. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
[TBL] [Abstract][Full Text] [Related]
3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
4. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports.
Momen Majumder MS; Haq SA; Rasker JJ
J Med Case Rep; 2023 Mar; 17(1):71. PubMed ID: 36855206
[TBL] [Abstract][Full Text] [Related]
6. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
[TBL] [Abstract][Full Text] [Related]
7. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
8. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
[TBL] [Abstract][Full Text] [Related]
9. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study.
Bastida G; Marín-Jiménez I; Forés A; García-Planella E; Argüelles-Arias F; Tagarro I; Fernandez-Nistal A; Montoto C; Aparicio J; Aguas M; Santos-Fernández J; Boscá-Watts MM; Ferreiro-Iglesias R; Merino O; Aldeguer X; Cortés X; Sicilia B; Mesonero F; Barreiro-de Acosta M
Dig Liver Dis; 2022 Jan; 54(1):76-83. PubMed ID: 34244110
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease.
Núñez-Gómez L; Mesonero-Gismero F; Albillos-Martínez A; López-Sanromán A
Gastroenterol Hepatol; 2018 Nov; 41(9):576-582. PubMed ID: 30054143
[TBL] [Abstract][Full Text] [Related]
12. [Extraintestinal manifestations of inflammatory bowel diseases and their management].
Garamszegi M
Orv Hetil; 2011 Apr; 152(17):663-71. PubMed ID: 21464024
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus, inflammatory bowel disease, and anti-TNFα.
Campos ST; Portela FA; Tomé L
Int J Colorectal Dis; 2017 May; 32(5):645-650. PubMed ID: 28084548
[TBL] [Abstract][Full Text] [Related]
14. Associations Between Obesity and the Effectiveness of Anti-Tumor Necrosis Factor-α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis.
Dai ZH; Xu XT; Ran ZH
Ann Pharmacother; 2020 Aug; 54(8):729-741. PubMed ID: 31955605
[No Abstract] [Full Text] [Related]
15. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
16. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease.
Schultheiss JPD; Mahmoud R; Louwers JM; van der Kaaij MT; van Hellemondt BP; van Boeckel PG; Mahmmod N; Jharap B; Fidder HH; Oldenburg B
Aliment Pharmacol Ther; 2021 Nov; 54(10):1298-1308. PubMed ID: 34559428
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty.
Kochar BD; Cai W; Ananthakrishnan AN
Dig Dis Sci; 2022 Feb; 67(2):622-628. PubMed ID: 33932198
[TBL] [Abstract][Full Text] [Related]
18. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
19. Cholelithiasis in inflammatory bowel disease. A case-control study.
Lorusso D; Leo S; Mossa A; Misciagna G; Guerra V
Dis Colon Rectum; 1990 Sep; 33(9):791-4. PubMed ID: 2202567
[TBL] [Abstract][Full Text] [Related]
20. Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center.
Hoffmann P; Krisam J; Stremmel W; Gauss A
Dig Dis; 2019; 37(1):33-44. PubMed ID: 30134234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
